Breast Cancer

Surviving cancer is hard enough, but what about the rare and unusual versions?

In essays by patients and colleagues, three nurses were honored for their generosity and life-changing compassion.

The FDA has expanded the approval of Ibrance (palbociclib) capsules in combination with endocrine therapy for male patients with hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer.

Create a digital health binder, improve communication, find clinical trials and get connected with three free mobile apps.

Susan G.Komen-Greater NYC announced today the members of its newly appointed Medical Advisory Committee.

Sometimes it takes a bigger candle to shine a light on our disease.

Here are the top 5 CURE stories for March 2019.

This week, the Food and Drug Administration (FDA) proposed changes to improve and modernize breast cancer screening. In their proposal, the FDA submitted amendments to the current regulations that would provide patients with more detailed information. This information, which would include breast density, would help patients make better decisions regarding their personal health care.

Despite emotional testimony from women who say their breast implants made them sick with cancer or autoimmune symptoms, the Food and Drug Administration (FDA) has no plans to ban the textured implants that are being blamed.

The FDA announced on March 27, 2019 that it is working to update mammography regulations, expanding the amount of information that mammography facilities must give patients and healthcare professionals.

Three sisters trace their family’s experiences with breast and ovarian cancer across generations.

By the time 14 months of treatment were through, I was watching a woman I no longer recognized and could not bear to look at in the mirror. I realized that to truly be a survivor, I had to readjust my expectations of myself.

Enormous progress has been made in breast cancer, yet many challenges remain, according to Ann H. Partridge, M.D., MPH.

In metastatic breast cancer, the brain MRI is often a special request for what you don't want but truly need.

Debu Tripathy, M.D., the editor in chief of CURE®, recently sat down at the Miami Breast Cancer Conference to discuss the importance of oncology nurses in breast cancer care and offered insight as to how they can keep up-to-date with the constant advancements in the field.

Adam Brufsky, M.D., Ph.D. discussed treatments for BRCA-positive breast cancer at the 2019 Miami Breast Cancer Conference.

Breast cancer is no laughing matter, but being able to find something to laugh about in the midst of the trial can be cathartic.

Of all the things that cancer left me with, scarred veins in my only good arm has been the worst. I have learned to treasure those techs who can find a good vein and hit it the first time.

In this week’s episode, we spoke with Linda Tantawi about Susan G. Komen Greater New York City, and how the organization is connecting communities to educate women about breast cancer.

Rose Gerber, of the Community Oncology Alliance, shared her story of participating in a clinical trial and hopes for others to help educate patients with breast cancer to increase participation moving forward.

At CURE’s patient-focused meeting at the 36th Annual Miami Breast Cancer Conference, Shannon Pulaski and Ellen Matloff discussed the importance of genetic counseling and learning more about one’s family health history.

The Food and Drug Administration (FDA) has granted an approval to Trazimera (PF-05280014; trastuzumab-qyyp), a Herceptin (trastuzumab) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Many people believe that genetic testing for cancer can only be beneficial for individuals with a strong family history of the disease, but that is not necessarily the case.

Can at-home DNA testing kits accurately help us discover important health information? What do we do with the information once we receive it? In this post, learn more about the pros and cons.

The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.